The BCL11B Knockout 769-P Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population derived from the human 769-P cell line, designed for targeted disruption of the BCL11B gene. This product provides a heterogeneous pool of edited cells, each carrying distinct loss-of-function mutations introduced by CRISPR/Cas9-mediated gene editing, enabling robust functional studies without clonal isolation. The polyclonal format preserves population-level genetic diversity, facilitating the investigation of BCL11B-dependent phenotypes in a biologically relevant context. Researchers can employ these cells to dissect gene regulatory networks, assess tumor suppressor mechanisms, and model disease-associated loss of BCL11B function in renal adenocarcinoma.
The parental 769-P cell line is a widely used model of human clear cell renal cell carcinoma (ccRCC), originally isolated from a primary renal adenocarcinoma. These cells retain characteristic epithelial morphology and genetic features of ccRCC, including dysregulated hypoxia and metabolic signaling. As a renal epithelial tumor model, 769-P cells provide a relevant system for studying oncogenic pathways, metastatic behavior, and therapeutic responses. The introduction of a BCL11B knockout into this background allows direct interrogation of the gene’s role in renal carcinogenesis, where its expression has been linked to tumor suppression and modulation of Wnt/??-catenin signaling.
BCL11B encodes a zinc finger transcription factor that interacts with the NuRD complex (including HDAC1 and HDAC2) and cooperates with RUNX1 and GATA3 to regulate lineage-specific gene expression. Upstream activators include the Notch1 intracellular domain (NICD), TCF7, LEF1, IL-7 receptor signaling, and ERK kinase cascades. BCL11B transcriptionally controls downstream targets such as CD4, CD8, TCR??/??, IL2, SOCS1, ID2, and ZBTB16. Through these interactions, BCL11B integrates Notch, Wnt/??-catenin, and T-cell receptor pathways to govern cell differentiation, proliferation, and apoptosis.
In renal adenocarcinoma, BCL11B is implicated in tumor suppression, with potential roles in Wnt/??-catenin modulation via TCF7 and LEF1. The 769-P knockout model permits dissection of BCL11B??s impact on epithelial-mesenchymal transition (EMT), cell adhesion, and crosstalk with Notch signaling??processes frequently dysregulated in ccRCC. This model facilitates the investigation of molecular mechanisms underlying renal tumorigenesis and may reveal novel therapeutic targets.
Typical applications include Western blotting and RT-qPCR for confirmation of BCL11B disruption and target gene analysis. Functional assays encompass cell proliferation, viability, migration/invasion, and apoptosis measurements. Transcriptomic profiling by RNA-seq and occupancy studies via ChIP-qPCR further elucidate BCL11B-dependent networks. These tools support investigations into Wnt signaling, tumor suppressor mechanisms, EMT, and drug sensitivity. Researchers can utilize this polyclonal knockout resource to address questions in cancer biology, immunology, and neurodevelopment. For further information, please contact Ascent Research.
